Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.28 USD
-0.10 (-0.18%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $55.28 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CYTK 55.28 -0.10(-0.18%)
Will CYTK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYTK
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
Other News for CYTK
Cytokinetics: Strategic Growth and Promising Cardiology Pipeline Justify Buy Rating
Insider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells Shares
Cytokinetics to provide an update on cardiac myosin modulation programs
Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc
BOXER CAPITAL, LLC Expands Stake in ITeos Therapeutics Inc